Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus ; volume:14 ; number:4 ; day:21 ; month:3 ; year:2024 ; pages:919-932 ; date:4.2024
Dermatology and therapy ; 14, Heft 4 (21.3.2024), 919-932, 4.2024
- Creator
-
Gargiulo, Luigi
Ibba, Luciano
Malagoli, Piergiorgio
Burroni, Anna G.
Chiricozzi, Andrea
Dapavo, Paolo
Ferrucci, Silvia M.
Gola, Massimo
Napolitano, Maddalena
Ortoncelli, Michela
Rossi, Maria T.
Sciarrone, Claudio
Costanzo, Antonio
Narcisi, Alessandra
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13555-024-01135-x
- URN
-
urn:nbn:de:101:1-2407092113362.101485514877
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gargiulo, Luigi
- Ibba, Luciano
- Malagoli, Piergiorgio
- Burroni, Anna G.
- Chiricozzi, Andrea
- Dapavo, Paolo
- Ferrucci, Silvia M.
- Gola, Massimo
- Napolitano, Maddalena
- Ortoncelli, Michela
- Rossi, Maria T.
- Sciarrone, Claudio
- Costanzo, Antonio
- Narcisi, Alessandra
- SpringerLink (Online service)
Other Objects (12)
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis
Atopic dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Skin microbiota of first cousins affected by psoriasis and atopic dermatitis
Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Biomarkers in Atopic Dermatitis
Neutrophils in Atopic Dermatitis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis
Atopic dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Skin microbiota of first cousins affected by psoriasis and atopic dermatitis
Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Biomarkers in Atopic Dermatitis
Neutrophils in Atopic Dermatitis
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Atopic dermatitis
Atopic dermatitis
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD
Skin microbiota of first cousins affected by psoriasis and atopic dermatitis
Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis
Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis
Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Biomarkers in Atopic Dermatitis